Novo Nordisk withdraws press statement – had misleading marketing
The Danish Maritime and Commercial High Court has ruled that a Novo Nordisk press announcement had misleading marketing.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Novo Nordisk has withdrawn a press statement on Tresiba, which was issued on Sep. 19, 2019, after the Danish Maritime and Commercial High Court has ruled that it contained misleading marketing, which Novo Nordisk announces on Monday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk submits obesity drug for FDA approval
For subscribers
